4-氨基-2-氟苯硼酸频那醇酯 | 819057-45-9

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯硼酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-2-氟苯硼酸频那醇酯
• 中文别名: 2-氟-4-氨基苯硼酸频哪醇酯；3-氟-4-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)苯胺
• 英文名称: 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
• 英文别名: 4-amino-2-fluorophenylboronic acid pinacol ester；3-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine
• CAS: 819057-45-9
• 化学式: C₁₂H₁₇BFNO₂
• mdl: MFCD09951877
• 分子量: 237.082
• InChiKey: FLMNWVXAEGUVNY-UHFFFAOYSA-N

物化性质

• 沸点：
  343.6±32.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.26
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Amino-2-fluorophenylboronic acid pinacol ester
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Amino-2-fluorophenylboronic acid pinacol ester
Ingredient name:
CAS number: 819057-45-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H17BFNO2
Molecular weight: 237.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

4-氨基-2-氟苯硼酸频那醇酯可作为药物和有机发光材料（LED）合成中的重要中间体。

反应信息

• 作为反应物：
  描述：

  4-氨基-2-氟苯硼酸频那醇酯 在 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 76.0h， 生成 N-{4-[2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]-3-fluorophenyl}-5-(4-fluorophenyl)-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydropyridine-3-carboxamide
  参考文献：
  名称：

  Pyridone Derivatives

  摘要：

  提供了抑制Axl并用于治疗由Axl高功能引起的疾病、与Axl高功能相关的疾病和/或伴随Axl高功能的疾病的新型化合物或其盐，或其晶体。提供了由式（1）所代表的吡啶酮衍生物，具有各种取代基或其盐，或其晶体（其中式（1）中的R1、R2、R3、R5、R6、A、W、X和n分别如规范中定义）。

  公开号：

  US20130281428A1
• 作为产物：
  描述：

  2-氟-4-硝基苯胺 在 亚硝酸特丁酯 、 5%-palladium/activated carbon 、 2-(4-联苯基)-5-苯基唑 、 氢气 作用下， 以 甲醇 、 乙腈 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 8.0h， 生成 4-氨基-2-氟苯硼酸频那醇酯
  参考文献：
  名称：

  Sandmeyer型转化合成三甲基锡烷基芳基硼酸酯化合物及其在化学选择性交叉偶联反应中的应用

  摘要：

  描述了一种基于Sandmeyer型反应的合成方法，可从硝基苯胺衍生物中获得锡和硼取代的芳烃。该转化可用于合成一系列官能化的三甲基锡烷基芳基硼酸酯。此外，还探索了Stille和Suzuki-Miyaura交叉偶联反应的化学选择性反应，并通过进行连续的一锅法式Stille和Suzuki-Miyaura交叉偶联反应合成了一系列m-和对-三苯基衍生物。

  DOI：

  10.1021/jo402618r

文献信息

• Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1
  作者：R. Kirk、A. Ratcliffe、G. Noonan、M. Uosis-Martin、D. Lyth、O. Bardell-Cox、J. Massam、P. Schofield、S. Hindley、D. R. Jones、J. Maclean、A. Smith、V. Savage、S. Mohmed、C. Charrier、A-M. Salisbury、E. Moyo、R. Metzger、N. Chalam-Judge、J. Cheung、N. R. Stokes、S. Best、M. Craighead、R. Armer、A. Huxley

  DOI：10.1039/d0md00174k

  日期：——

  and topoisomerase IV inhibitors that demonstrate potent activity against a range of Gram-positive and selected Gram-negative organisms, including clinically-relevant and drug-resistant strains. In part 1, we present a detailed structure activity relationship (SAR) analysis that led to the discovery of our previously disclosed compound, REDX05931, which has a minimum inhibitory concentration (MIC) of

  针对细菌感染的药物有效性令人震惊的下降，迫切需要开发新的抗菌剂来绕过细菌耐药机制。我们在此报告了一系列 DNA 促旋酶和拓扑异构酶 IV 抑制剂，它们对一系列革兰氏阳性和选定的革兰氏阴性生物体（包括临床相关和耐药菌株）表现出有效的活性。在第 1 部分中，我们提出了详细的构效关系 (SAR) 分析，导致我们发现了我们之前公开的化合物 REDX05931，该化合物对耐氟喹诺酮类金黄色葡萄球菌的最小抑制浓度 (MIC) 为 0.06 μg mL -1。虽然在体外 hERG 和 CYP 抑制阻止了进一步的发展，它验证了一种合理的设计方法来解决这一紧迫的未满足的医疗需求，并为进一步优化提供了一个支架，在第 2 部分中介绍。
• [EN] COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DE CD73 ET LEURS INDICATIONS
  申请人：PLEXXIKON INC

  公开号：WO2021216898A1

  公开（公告）日：2021-10-28

  Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

  披露了公式(I)的化合物：或其药用盐、溶剂化物、互变异构体、立体异构体或氘代类似物，其中R1、R2、R3、A、E、L和G如本公开的任何实施方案所述；其组合物；及其用途。
• [EN] DIHYDROOXADIAZINONES<br/>[FR] DIHYDROOXADIAZINONES
  申请人：BAYER AG

  公开号：WO2019025562A1

  公开（公告）日：2019-02-07

  The present invention provides dihydrooxydiazinone compounds of general formula (I) : in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

  本发明提供了一般式(I)的二氢氧二氮酮化合物：其中R1、R2、R3和R4如本文所定义，制备所述化合物的方法，用于制备所述化合物的中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖性疾病，作为唯一药剂或与其他活性成分组合使用。
• [EN] IL-17A MODULATORS<br/>[FR] MODULATEURS DE IL-17A
  申请人：SANOFI SA

  公开号：WO2021239745A1

  公开（公告）日：2021-12-02

  The present invention relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.

  本发明涉及一种具有IL-17A调节剂作用的化合物。这些化合物具有本文中定义的结构式I。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗与IL-17A活性调节相关的疾病或疾病中的应用。
• Discovery of 4,6- and 5,7-Disubstituted Isoquinoline Derivatives as a Novel Class of Protein Kinase C ζ Inhibitors with Fragment-Merging Strategy
  作者：Masakazu Atobe、Takayuki Serizawa、Natsumi Yamakawa、Kenichiro Takaba、Yukiko Nagano、Toshiaki Yamaura、Eiichi Tanaka、Atsutoshi Tazumi、Shino Bito、Masashi Ishiguro、Masashi Kawanishi

  DOI：10.1021/acs.jmedchem.0c00449

  日期：2020.7.9

  to the discovery of other challenging kinase inhibitors without protein–ligand structural information. Furthermore, our optimization effort identified the highly potent and orally available 5,7-isoquinoline 37 from the second chemical series. Compound 37 showed good efficacy in a mouse collagen-induced arthritis model. The in vivo studies suggest that PKCζ inhibition is a novel target for rheumatoid

  使用我们的片段合并策略，可以快速鉴定出两个化学系列的新型蛋白激酶Cζ（PKCζ）抑制剂，即4,6-二取代和5,7-二取代的异喹啉。该方法包括生化筛选高浓度的单取代异喹啉片段文库，然后将命中的异喹啉片段合并为单个化合物。我们的策略可以应用于没有蛋白质-配体结构信息的其他具有挑战性的激酶抑制剂的发现。此外，我们的优化工作还确定了第二化学系列中高效的口服5,7-异喹啉37。化合物37在小鼠胶原蛋白诱发的关节炎模型中显示出良好的疗效。体内研究表明，PKCζ抑制是类风湿性关节炎（RA）的新靶标，并且5,7-二取代异喹啉37具有阐明PKCζ抑制的生物学后果的潜力，特别是在对RA的治疗干预方面。